Mmbg Investment Advisors CO. Sells 25,260 Shares of Pfizer Inc. $PFE

Mmbg Investment Advisors CO. reduced its stake in Pfizer Inc. (NYSE:PFE) by 41.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,875 shares of the biopharmaceutical company’s stock after selling 25,260 shares during the period. Mmbg Investment Advisors CO.’s holdings in Pfizer were worth $893,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Franklin Resources Inc. increased its stake in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after acquiring an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after acquiring an additional 5,202,884 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Wolfe Research reissued an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. Guggenheim boosted their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.61.

Pfizer Stock Up 0.1%

Pfizer stock opened at $25.92 on Tuesday. Pfizer Inc. has a fifty-two week low of $22.88 and a fifty-two week high of $28.75. The stock has a market cap of $147.72 billion, a PE ratio of 19.79 and a beta of 0.35. The firm’s 50-day simple moving average is $26.84 and its 200 day simple moving average is $26.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.